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Abstract
Background: Arrhythmogenic cardiomyopathy (ACM) is a genetic autosomal disease characterized by abnormal
cell-cell adhesion, cardiomyocyte death, progressive fibro-adipose replacement of the myocardium, arrhythmias and
sudden death. Several different cell types contribute to the pathogenesis of ACM, including, as recently described,
cardiac stromal cells (CStCs). In the present study, we aim to identify ACM-specific expression profiles of human
CStCs derived from endomyocardial biopsies of ACM patients and healthy individuals employing TaqMan Low
Density Arrays for miRNA expression profiling, and high throughput sequencing for gene expression quantification.
Results: We identified 3 miRNAs and 272 genes as significantly differentially expressed at a 5% false discovery rate.
Both the differentially expressed genes as well as the target genes of the ACM-specific miRNAs were found to be
enriched in cell adhesion-related biological processes. Functional similarity and protein interaction-based network
analyses performed on the identified deregulated genes, miRNA targets and known ACM-causative genes revealed
clusters of highly related genes involved in cell adhesion, extracellular matrix organization, lipid transport and
ephrin receptor signaling.
Conclusions: We determined for the first time the coding and non-coding transcriptome characteristic of ACM
cardiac stromal cells, finding evidence for a potential contribution of miRNAs, specifically miR-29b-3p, to ACM
pathogenesis or phenotype maintenance.
Keywords: Arrhythmogenic cardiomyopathy, Cardiac stromal cells, microRNA expression, Gene expression,
Genomics, Transcriptome profiling
Background
Arrhythmogenic cardiomyopathy (ACM) is a genetic
autosomal disease that affects about 1 in 2000–5000
young people, in particular athletes [1, 2]. It is mainly
caused by mutations in genes encoding desmosomal pro-
teins even if other genes have been associated with ACM
too [3]. ACM is characterized by cardiomyocyte death and
progressive accumulation of fibro-adipose tissue, but the
pathogenic mechanisms remain still largely unknown.
Abnormal cell-cell adhesion and intracellular signaling,
caused by the mutations, are thought to alter Wnt/β-ca-
tenin [4] and Hippo [5] pathways resulting in myocyte
death, fibro-adipogenesis, gap junction and ion channel
remodeling. This leads to myocardium wall thinning, pro-
gressive heart failure, inefficient current conduction, and
life threatening arrhythmias [6]. For a long time, ACM has
been considered a cardiomyocyte-specific disease, but this
concept has been questioned when other cell types were
found to be implicated in ACM pathogenesis. In particu-
lar, cardiac stromal cells (CStCs), an abundant cardiac cell
population with differentiation potency [7] and a role in
cardiac homeostasis and remodeling during pathological
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conditions [8], have recently been characterized as a
source of adipocytes in ACM [8]. Human primary CStCs
from ACM patients express desmosomal proteins and
show, compared to healthy controls, a greater propensity
to undergo adipogenic differentiation in vitro in a PKP2-
and Wnt pathway-dependent fashion [8]. Importantly,
CStCs can contribute to the formation of adipose tissue in
the ACM affected heart.
While extensive characterizations have been per-
formed on the genetic basis of this disease, only few
studies have been conducted investigating differences at
transcriptional levels [9–11]. The present work ad-
dresses, for the first time, the characterization of the
ACM-specific coding and non-coding transcriptome in
CStCs. To this end we compared expression of genes
and miRNAs in cells derived from diagnostic biopsies of
ACM patients or controls. In order to reveal biological
pathways potentially involved in ACM we performed
category enrichment and network analyses on the differ-
entially expressed genes and validated target genes of
the deregulated miRNAs.
Methods
Biological samples and cell culture
Biopsy samples were obtained from ACM patients’ right
ventricle during diagnostic procedures in the area adja-
cent to the electroanatomical scar. Control samples were
obtained from the right ventricle of explanted hearts of
cadaveric donors (healthy hearts of organ donors). To
limit the variability due to regional differences, we se-
lected small portions of the endocardium in the right
ventricle free wall of the donors’ hearts, as this matches
the most likely source of ventricular biopsies in ACM
patients. All enrolled individuals are males aged between
37 and 64 (mean age for ACM patients: 47.6, standard
deviation 8.6, mean age for controls: 48.2, standard devi-
ation 7.8). All ACM patients fulfill definite ACM diagno-
sis as defined by the Task Force 2010 criteria (either two
major criteria or one major and two minor or four
minor). PKP2 mutations in ACM patients were deter-
mined by Sanger sequencing. Samples, both from ACM
patients and control individuals, were processed, as pre-
viously described, to obtain CStCs [7] on which the ex-
pression profiling was performed. Adherent cells were
cultured, propagated and used between passage 3 and 9.
As previously described [7], mesenchymal lineage was
confirmed and endothelial and hematopoietic origin was
excluded through flow cytometry analysis of surface
markers. See Table 1 for an overview of samples, clinical
data and experiments in which they were included.
RNA preparation
RNA was TRIZOL-extracted and quantified with a
NanoDrop ND-1000 Spectrophotometer. RNA quality
was assessed by an Agilent 2100 Bioanalyzer (Small
RNA Kit) for miRNA expression and by an Experion
Table 1 Characteristics of enrolled subjects
ID Used for Mutations Arrhythmias Dysfunction,structural and tissue alterations ECG
abnormalities
ACM
ACM1 m,t,mv,tv PKP2:1643delG PVCs; ventricular fibrillation RV wall hypokinesia; LV and RV dilation; fibro-adipose
substitution
Inverted T-
waves
(5/1)
ACM2 t,mv,tv PKP2:c.1881delC n.c. n.c. n.c. (4/1)
ACM3 t,mv,tv n.a. n.c. n.c. n.c. (1/2)
ACM4 m,mv,tv PKP2:2013delC Arrhythmic storm;
sustained VT
RV bulging; RV subendocardic trabeculation; fibro-adipose
substitution
(3/1)
ACM5 m,mv n.a. Arrhythmic storm;
sustained VT
RV wall hypokinesia; fibro-adipose substitution Inverted T-
waves
(2/1)
ACM6 mv,tv n.a. PVCs RV dilation and bulging; RV wall hypokinesia (2/1)
ACM7 tv,mv PKP2:c.548G > A n.c. n.c. n.c. (3/0)
ACM8 tv,mv n.a. n.c. n.c. n.c. (3/0)
CTRL1 m,t,mv,tv n.a.
CTRL2 m,t,mv,tv n.a.
CTRL3 m,t,mv,tv n.a.
CTRL4 tv n.a.
CTRL5 tv n.a.
CTRL6 mv,tv
CTRL7 mv,tv
All are male individuals aged 37 to 64. Abbreviations: n.a. Not available, PVC Premature ventricular contractions, VT Ventricular Tachycardia, m Whole genome
miRNA screening, t Whole genome transcriptome analysis, mv miRNA validation, tv Transcriptome validation. n.c.: not shown because consent for publication not
signed. Column ACM: number of diagnostic criteria based on ACM task force 2010 in the form (major/minor)
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electrophoresis system (RNA High Sense Analysis Kit,
Bio-Rad) for gene expression profiling. Only high quality
RNAs (A260/280 and A260/230 ratios > 1.8 and an
RQI > 9.5) were used for subsequent analyses.
miRNA expression analysis
miRNA expression was measured by TaqMan Low
Density Arrays (TLDA, Human MicroRNA Panel A and
B Card Sets v3.0, Applied Biosystems) on 480 ng of total
RNA from 3 ACM patients and 3 healthy subjects using
a 7900TH System (Applied Biosystems) following manu-
facturer’s instructions. The complete data set consisted
of 24 TLDAs: 2 replicates for each sample and two
cards, A and B, for each. Primary data analysis was con-
ducted with SDS RQ manager (Applied Biosystems) ap-
plying a manual threshold (0.2) and baseline (based on
cycles 10–16). Further analysis was performed in R (ver-
sion 3.4.2). The data was normalized with the global
geometric mean scaling method [12]. miRNA assays
were annotated to miRBase v20 using the LifeTech on-
line search tool. Replicated measurements per individual
were averaged prior to differential expression analysis
and all assays that did not yield a valid measurement in
at least 2 out of the 3 individuals in one of the two sam-
ple groups (because their measurements were flagged by
the SDS software as “Undetermined” or “No amplifica-
tion in well”) were excluded. This reduced the data set
from 768 assayed to 208 detected miRNAs. Significance
of differential expression was assessed with the moder-
ated t-test [13], p-values were adjusted for multiple hy-
pothesis testing with the method from Benjamini and
Hochberg controlling the false discovery rate (FDR) [14].
miRNAs with an adjusted p-value padj < 0.05 were con-
sidered significant.
High throughput sequencing and data analysis
Paired-end mRNA-sequencing libraries were prepared
using the Illumina TruSeq RNA Sample Prep Kit v2-Set
A starting from 1 μg of total RNA obtained from CStCs
of 3 ACM patients and 3 healthy controls, following
manufacturer’s instructions. Samples were multiplexed
and sequenced on 4 lanes of an Illumina HiSeq2000
resulting in between 53 and 85 million read pairs per
sample and a high average base call quality (Qphred
score > 35). Subsequent analysis was performed in R
(https://www.r-project.org, version 3.4.2, Bioconductor
version 3.5). The 100 nt-long raw reads were filtered re-
moving all reads with 7 or more undetermined nucleo-
tides and subsequently trimmed as soon as 3 of 5
consecutive nucleotides in a read’s sequence had a
base-call quality Qphred < 20. Finally, all reads shorter
than 41 nt were removed. Alignment of the reads was
performed against genome GRCh38 (Ensembl 81) using
GSNAP [15].
Gene quantification was performed using GenomicA-
lignments [16] counting the number of reads falling
completely within the exons of a gene, not considering
multi-mapping reads or reads with a low alignment
quality (phred score < 30). Genes with a normalized read
count < 10 in both sample groups were removed, redu-
cing the data set from 60,411 human genes defined in
Ensembl to 18,076. Differential gene expression analysis
was performed using DESeq2 [17] disabling the auto-
matic pre-filtering. Raw p-values were adjusted for mul-
tiple hypothesis testing using the method from
Benjamini and Hochberg [14]. All genes with an ad-
justed p-value padj < 0.05 were considered significant.
Quantitative reverse transcriptase–polymerase chain
reaction
One μg of total RNA was reverse transcribed using the
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen),
according to manufacturer’s instructions. cDNA was
amplified using TaqMan® Universal PCR Master Mix
(Applied Biosystems). For evaluation of JUP expression,
cDNA was amplified by SYBR-GREEN qPCR. miRNA
expression was measured with TaqMan assays for the in-
dividual miRNAs. Real-time reactions were performed
following manufacturer’s instructions on a CFX96™
RT-qPCR Detection System (Bio-Rad, USA). See ex-
tended Material and Methods in the Supplement for the
list of primers and assays.
RT-qPCR data analysis was performed in R. Two tech-
nical replicates per sample were averaged and normal-
ized against house-keeping control TBP (for genes) or
miR-28-3p (for miRNAs) to yield the ΔCq values [18].
miR-28-3p was selected due to its stable expression
across all samples in the whole genome miRNA expres-
sion analysis. Where present, measurements in RNA
from the same individual but from different experi-
ments/passages were averaged prior to differential ex-
pression analysis. Significance of differential expression
was assessed using the Student’s t-test.
Category enrichment analysis
The GOstats package [19] was used for category enrich-
ment analyses, with categories representing either sets of
genes annotated to pathways in the Reactome database,
or to terms from one of the 3 Gene Ontologies Bio-
logical Process, Cellular Component or Molecular Func-
tion. Genes considered to be expressed in the present
data set were used as background gene set. The p-values
from the hypergeometric tests were adjusted for multiple
hypothesis testing using the Bonferroni method and
pathways/GO terms with an adjusted p-value < 0.05
were considered significant.
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miRNA target gene and host gene analysis
Validated miRNA target gene information was taken
from the miRTarbase (version 6.1) [20] and the analysis
conducted using our “mirtarbase” R-package (https://
github.com/jotsetung/mirtarbase). For identification of
potential miRNA host genes/primary transcription units
[21] we used our “mirhostgenes” R-package (https://
github.com/jotsetung/mirhostgenes) with host gene pre-
dictions for miRBase v21 and genes defined in Ensembl
version 81.
Systematic evaluation of the downregulation of
ACM-miRNA target genes was performed as follows: for
each miRNA, the average M-value (representing the dif-
ferential expression of the gene) was calculated across all
of its target genes and compared to average M-values of
randomly selected, same-sized, sets of miRNA target
genes in a permutation test (1000 permutations). The
p-value represents the fraction of average M-values of
the random gene sets that were < = the average M-value
of the miRNA’s target genes (one-tailed test). Back-
ground genes were selected randomly among validated
(and expressed) target genes of expressed miRNAs. We
additionally used a Student’s t-test to test the alternative
hypothesis of an average M-value < 0.
Gene network analysis
Gene interaction networks were defined using informa-
tion from BioPlex [22] (version 4), mentha [23] (human
data release 2015.11.27), STRING [24] (version 10, re-
quiring confidence score of at least 0.9), and a functional
similarity network [25] based on Gene Ontology (GO)
biological process annotations (GO version 2015.09).
Only genes that yielded a read count in the present tran-
scriptome data set or that are expressed in the heart tis-
sue [26] were included in the networks. Clusters within
each network were identified using ClusterOne [27] with
default parameters, requiring at least four genes per clis-
ter in the BioPlex/mentha/STRING network and five
genes in the functional similarity network. Full network
analysis results are presented on https://gemex.eura-
c.edu/bioinf/acm/. Network visualizations were created
using python-igraph [28] and Cytoscape.js [29] and
Cytoscape, GO annotations and enrichments (FDR < 5%,
backgrounds comprising all genes in the respective net-
works) were computed using Dintor [30].
Results
ACM-specific miRNAs
To delineate the miRNA expression profile characteristic
for ACM cells, we extracted RNA from CStCs of 3 ACM
patients and 3 (sex and age matched) control individuals
and subjected it to whole genome miRNA expression pro-
filing. We identified the 3 miRNAs miR-520c-3p,
miR-29b-3p and miR-1183 to be significantly differentially
expressed at a 5% FDR (i.e. with a padj < 0.05; Fig. 1b), all
of them being more than 4-fold higher expressed in ACM
than in control samples (Table 2; the complete results are
provided in Additional file 1). For validation, we per-
formed RT-qPCR measurements of miR-520c-3p and
miR-29b-3p in RNA samples from the same 3 ACM and 3
control individuals, but from different passages in two
separate experiments, and, to further strengthen the bio-
logical significance of the results, also in cells from 5 add-
itional ACM patients and 3 additional controls. Validation
was thus performed in RNA samples from 8 ACM pa-
tients and 5 control individuals (see Table 1 for clinical in-
formation of the individuals).
Differential expression was confirmed for miR-29b-3p
but failed for miR-520c-3p, whose expression was below
the detection levels in all tested samples (Table 2).
To identify biological pathways being potentially influ-
enced by the differential expression of the identified
miRNAs, we next performed Gene Ontology and Reac-
tome pathway enrichment analyses on their target genes.
We defined target genes using miRTarBase [20] and, by
restricting to only high confidence target genes, identi-
fied 84 genes (77 target genes for miR-29b-3p and 7 for
miR-520c-3p, no target gene was reported for
miR-1183). These were tested for enrichment in Reac-
tome pathways against a background gene set consisting
of the 1486 validated target genes of all 208 expressed
miRNAs and pathways related to extracellular matrix
organization, cell-matrix adhesion and collagen forma-
tion were identified (Table 3). The results from the GO
enrichment analysis for biological process, cellular com-
ponent and molecular function supported this finding
(Tables S1-S3 in Additional file 2).
Since these results based mainly on target genes of
miR-29b-3p, we repeated the analysis considering also
target genes with lower supporting evidence and thus in-
creased the number of target genes from the other two
miRNAs in the analysis (Additional file 2: Table S4). The
results from this analysis were comparable (Additional
file 2: Tables S6-S9).
Summarizing, we identified 3 miRNAs (miR-520c-3p,
miR-29b-3p and miR-1183) to be differentially expressed
between ACM patient-derived and control CStCs and
confirmed the de-regulation of miR-29b-3p in an ex-
tended data set including samples from in total 8 ACM
patients and 5 controls. We also found evidence for a
potential contribution of miR-29b-3p to ACM develop-
ment by targeting proteins involved in extracellular
matrix organization.
Genes differentially expressed between ACM and control
samples
In order to delineate differences in the gene expression
profiles between ACM and control CStCs, we subjected
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poly-A enriched RNA from 3 ACM and 3 control sam-
ples from different individuals to high throughput se-
quencing for whole genome expression analysis. Gene
expression quantification was performed by counting the
reads completely aligned within the exon boundaries of
any transcript. Most of these reads were assigned to pro-
tein coding genes but a considerable number was also
assigned to genes from other biotypes such as lincRNAs
or snRNAs, allowing quantification of some non-coding
genes in the present experiments too (see Figure S1 in
Additional file 2 for an overview of read counts per gene
biotype). A principal component analysis (PCA) per-
formed on the gene expression profiles showed the ex-
pected separation of ACM and CTRL samples (Fig. 2a),
but did also suggest the presence of an unknown con-
founding factor represented by PC1. Including a variable
describing the above factor into the linear model and
thus alleviating for its potential influence, we performed
gene-wise tests for differential expression and identified
272 genes more than two-fold differentially expressed at
a 5% FDR (i.e. with an padj < 0.05; Fig. 2b and Table S10
in Additional file 2; Additional file 3 for the complete
results).
For validation, we selected 4 significantly differentially
expressed genes (PCDH1, SAXO2, SEMA3D, NEDD9).
These genes were selected because they were among the
most significant differentially expressed genes with a
previously described relation to cardiac diseases. For val-
idation of the RNA-seq results we assessed their differ-
ential expression in RNA samples from the same
individuals, but from cells from different passages and
experiments (to ensure the results being independent of
the passage/experiment). Regulation of all 4 genes was
reconfirmed (Additional file 2: Table S11). To test and
validate the biological significance of their regulation in
the context of ACM, we evaluated differential expression
of the genes in an extended data set consisting of RNA
from CStCs derived from 7 ACM patients and 7 control
individuals (Table 4).
Regulation of SAXO2 and NEDD9 was reconfirmed
also on the larger data set, while PCDH1 and SEMA3D,
despite being on average more than two-fold, did not
reach significance levels.
Subsequent Gene Ontology enrichment analyses of the
differentially expressed genes revealed significant enrich-
ment in cellular component terms “integral component
of plasma membrane” and “intrinsic component of
membrane” (Additional file 2: Table S12) and biological
process terms “dopamine transport” and “catecholamine
secretion” (Additional file 2: Table S13). Together, these
results indicate an enrichment of membrane associated
genes among the identified differentially expressed
genes.
We next evaluated the expression of genes with
ACM-associated variants [31] and, with the exception of
JUP, did not find any of these genes being differentially
expressed (Additional file 2: Table S14). Interestingly,
five of them, CTNNA3, DES, DSC2, PLN and RYR2, were
not expressed, or expressed below the detection limit, in
any of the analyzed samples. From the remaining genes,
4 were highly expressed (LMNA, DSP, TMEM43 and
JUP), and 4 moderately (TTN, TGFB3, DSG2 and PKP2).
Fig. 1 miRNA expression profiling. a: Principal component analysis (PCA) result showing the grouping of samples based on their miRNA
expression. b: Volcano plot showing the extent (M-value, x-axis) and significance (−log10 of Benjamini and Hochberg adjusted p-values padj, y-axis)
of differential expression between ACM and control samples for each miRNA. Positive M-values indicate higher expression in ACM, negative
higher expression in control samples
Table 2 ACM-specific miRNAs
padj M ΔCq ACM ΔCq CTRL pval Mval
hsa-miR-520c-3p 0.012 6.8 29.9 36.7 – –
hsa-miR-29b-3p 0.020 3.0 28.6 31.6 2.0 0.047
hsa-miR-1183 0.040 4.0 30.7 34.7 n.a. n.a.
padj: p-value adjusted for multiple hypothesis testing assessing the significance
of differential expression. M: log2 fold-change value. ΔCq ACM and ΔCq CTRL:
normalized average expression estimates in ACM and control samples. pval
and Mval: p- and M-values from the validation experiments. n.a.: test
not performed
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Expression of JUP was highly variable between
within-group samples and was on average higher in ACM
than in CTRL samples. This was reconfirmed by real-time
RT-qPCR measurements in the same RNA (Additional file
2: Figure S2). The observed differential expression did how-
ever disappear if additional samples were considered (Add-
itional file 2: Figure S2). Thus, in line with previous reports
[8], no biologically significant differential expression of
ACM associated genes could be observed on mRNA levels.
Taken together, the results from the gene expression
analysis are in agreement with the miRNA target gene
analysis, indicating that an integral part of the deregu-
lated genes are functional in the outer cell membrane.
Combined miRNA and gene expression analysis
Given that some miRNAs are known to repress their tar-
get genes mainly by destabilizing their mRNA [32], we
combined the miRNA and gene expression data set to
evaluate whether a downregulation of target genes of the
identified ACM-specific miRNAs is already observable
on mRNA levels. Indeed, the average log2 fold-change
values (M-values) of target genes for most miRNAs were
Table 3 Reactome pathway enrichment analysis results of miRNA target genes
Pathway name padj Count Size A B
Extracellular matrix organization 0.000 32 82 30 2
Assembly of collagen fibrils and other multimeric structures 0.000 14 22 14 0
Collagen formation 0.000 15 26 15 0
ECM proteoglycans 0.000 12 20 11 1
Non-integrin membrane-ECM interactions 0.000 13 25 13 0
Degradation of the extracellular matrix 0.000 16 42 15 1
Integrin cell surface interactions 0.000 14 33 13 1
Collagen biosynthesis and modifying enzymes 0.000 9 16 9 0
Platelet degranulation 0.001 11 29 10 1
Response to elevated platelet cytosolic Ca2+ 0.001 11 29 10 1
Collagen degradation 0.002 10 24 10 0
Platelet activation, signaling and aggregation 0.006 16 67 15 1
Elastic fibre formation 0.009 8 17 8 0
Laminin interactions 0.011 6 9 6 0
Collagen chain trimerization 0.012 7 13 7 0
Crosslinking of collagen fibrils 0.014 5 6 5 0
NCAM1 interactions 0.046 5 7 5 0
Column padj: p-value adjusted for multiple hypothesis testing using the method from Bonferroni assessing the significance of enrichment, Count and Size: number
of target genes of ACM-miRNAs or of all detectable miRNAs associated with the pathway. Columns A and B contain the number of target genes of miR-29b-3p
and miR-520c-3p
Fig. 2 mRNA expression profiling. a: PCA results representing the grouping of samples based on their whole genome gene expression profile. b:
Volcano plot showing the extent (M-value, x-axis) and significance (−log10 of Benjamini and Hochberg adjusted p-values padj, y-axis) of differential
expression between ACM and control samples for each gene. The dashed horizontal and vertical lines represent the cut-off values used to define
differentially expressed genes
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slightly negative, representing an on average lower ex-
pression of these genes in ACM than in control samples
(Additional file 2: Tables S16-S17). To test whether this
observed repression was larger than expected by chance,
we compared it to average M-values of same-sized sets
of randomly selected target genes of expressed miRNAs.
The resulting p-values from these tests are listed in
Table 5. Of these, the average M-values of miR-29b-3p
target genes and the combination of all of the miRNAs’
target genes were significant suggesting that the identi-
fied miRNAs are functional and that a tendency of re-
pression is already detectable on mRNA levels.
Most human miRNAs are encoded in introns of pro-
tein coding genes and share in many instances the pri-
mary transcription unit with these [33]. Using our
mirhostgenes R-package we identified potential host
genes for 2 of the ACM-specific miRNAs: the two lincR-
NAs C1orf132 and AC058791.1 for miR-29b-3p and the
protein coding gene SP4 for miR-1183. While none of
these were significantly differentially expressed, they all
showed the expected trend of a higher expression in
ACM samples (Additional file 2: Table S18). According
to the protein expression atlas [26], SP4 is expressed in
heart muscle tissue. No protein expression data is avail-
able for the other two as they are non-coding. According
to the Ensembl Expression Atlas however, also C1orf132
is highly expressed in heart tissue. These miRNAs might
therefore, in addition to CStCs, also be expressed in
other cell types of the heart.
In conclusion, our analysis on the expression of the
miRNAs’ targets genes on mRNA levels suggests the
identified miRNAs being functional in the analyzed cells
which strengthens the evidence for their potential in-
volvement in ACM.
Gene network analysis
We next performed gene network analyses to evaluate
relations between regulated genes, target genes of differ-
entially expressed miRNAs and genes with known
ACM-related genetic variants. Such networks allow to
identify groups of input gene products that physically
interact, that are part of common protein complexes, or
that are functionally related. We built a first network
based on functional annotations (functional network) of
the genes mentioned above. Connected nodes in this
network represent thus genes implicated in common
biological processes. Clusters of highly connected com-
ponents were identified and biological processes charac-
teristic for each cluster were determined. Overlapping
clusters were further combined resulting in a total of 6
functional modules (FM; resulting network model shown
in Fig. 3; see Additional file 4 for module details). The
largest, FM_1, consisted of a large number of miRNA
targets that are implicated in extracellular matrix
organization. Module FM_2 contained multiple tran-
scription factors that are up- or down-regulated in
ACM. Module FM_4 included the largest number of dif-
ferentially expressed genes (9), four of which encoding
lipid transport proteins (ABCC3, ATP8A1, ESYT3 and
ABCG1). Genes in FM_5 are related to cardiac muscle
cell adhesion and most of them encode desmosomal
proteins. Modules FM_3 and FM_6 contained mostly
genes involved in signaling processes (small GTPase me-
diated signal transduction for FM_3 and G-protein
coupled receptor signaling for FM_6).
A second gene network was generated using functional
relationships from STRING and protein interactions
from BioPlex and mentha (combined network). For this
analysis we included all genes with a valid read count in
the present dataset or which, according to the protein
atlas [26], are expressed in the heart tissue. Highly con-
nected clusters of genes were identified as above and
those with more than one differentially expressed gene,
ACM-miRNA target gene or gene with ACM-related
variants were further investigated. The full results are
shown online at https://gemex.eurac.edu/bioinf/acm/
(“Clusters in full networks”). Some of the identified clus-
ters showed considerable overlap with the previously
identified functional modules, such as c0515 that over-
laps FM_5, or the collagen genes containing cluster
c0502 resembling FM_1. Additional promising clusters
were identified too, like the cell adhesion related cluster
c0997 that contained two genes from the protocadherin
family (PCDH12 and PCDH17), both being lower
expressed in ACM than in control samples, or cluster
Table 4 Validation of gene regulations in an extended data set
Gene name pseq Mseq ppcr Mpcr
PCDH1 0.00 −3.69 0.13 −1.42
SAXO2 0.00 2.72 0.03 2.42
SEMA3D 0.00 1.89 0.28 1.08
NEDD9 0.00 −1.57 0.01 −1.32
Columns pseq and Mseq: p-value adjusted for multiple hypothesis testing and
log2 fold change in expression from the RNA-seq experiment, ppcr and Mpcr: p-
value and log2 fold change in expression from the RT-qPCR experiment. The
RT-qPCR measurements were conducted in RNA samples from CStCs from 7
ACM patients and 7 control individuals
Table 5 Repression of target genes of ACM-specific miRNAs in
ACM samples on mRNA levels
miRNA Average M pt pperm Gene count
miR-29b-3p −0.10 0.01 0.03 66
miR-520c-3p −0.09 0.12 0.28 6
All −0.10 0.01 0.03 72
Average M: average log2 fold-change of all target genes of the miRNA, pt: p-
value from a Student’s t-test testing the alternative hypothesis of an average
M-value < 0, pperm: p-value from the permutation test and Gene count: number
of validate target genes considered in the analysis
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c0065 that links the differentially expressed gene
ITGA10 with the ACM-miRNA target gene ITGB1 and
with all of its 10 genes being also involved in extracellu-
lar matrix organization. Another interesting cluster
(c0703) consisted of 16 genes, 6 of which were related to
cell adhesion. From these genes, two, the ephrin recep-
tors EPHA4 and EPHB2, were up-regulated and one, the
EFNB class ephrin ligand EFNB2, was down-regulated in
ACM cells (Additional file 2: Figure S3).
Summarizing, the functional networks provide an over-
view of the main biological processes in which both the
ACM differentially expressed genes and the ACM-specific
miRNA targets play a role. The results indicate that, in
addition to cell adhesion related processes, deregulated
genes are also involved in lipid transport, inflammation
and fibrosis related processes.
Discussion
In this study, we performed for the first time a compre-
hensive characterization of the coding and non-coding
transcriptome of cardiac stromal cells derived from
ACM patients and control individuals. Expression stud-
ies in ACM have been performed in the past [9–11], but
these were either focused on protein coding genes or on
miRNAs and were conducted on RNA extracted directly
from heart tissue biopsies or even from explanted hearts.
Of the 199 deregulated genes from Gaertner et al. [9] we
could detect 191 in our samples, but none of them were
Fig. 3 Functional network of differentially expressed genes, CStCs-ACM-miRNA target genes and genes with known ACM-related variants. Nodes
represent genes, labeled with their official HGNC symbol, edges functional similarities between genes. Black lines indicate functional modules that
represent gene clusters and their common functional annotation
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differentially expressed. Similarly, none of the 3 genes
reported by Akdis et al. [10] were deregulated in our
samples. Gaertner et al. performed expression profiling
in RNA extracted directly from explanted (final stage)
ACM- or non-failing hearts, Akdis et al. in RNA from
biopsies, that were even reported to be inhomogeneous
in the original article [10]. Missing concordance between
studies can thus most likely be attributed to the different
sample types being studied, different cell types, or to in-
homogeneous cell populations. By performing all ana-
lyses in cells of the same type we ensured the results
being independent of cell type or tissue-specific differ-
ences, limiting the validity of our conclusions however
to the cardiac stromal cells analyzed. Recently, 28 miR-
NAs have been described to be differentially expressed
in mouse cardiac muscle cells (HL-1) after
shRNA-mediated PKP2 knock-down [34]. We evaluated
the expression for the human equivalents for 12 of these
miRNAs in our CStCs. Only two of them, miR-671-3p
and miR-487b-3p showed a tendency of differential ex-
pression, albeit not reaching significance levels (Add-
itional file 2: Table S15). Also in this case, differences
can be explained by different cell types being studied,
different species and also the fact that PKP2
knock-down was artificially induced by shRNA silencing
[34].
In our analysis, we identified 3 miRNAs to be differen-
tially expressed between CStCs from ACM and control
samples. Two of them (miR-29b and miR-1183) have
previously been related to a pathway associated with
ACM or other cardiac diseases. miRNAs from the
miR-29 family have been shown to play a role in cardiac
fibrosis after myocardial infarction targeting collagen,
fibrillin and elastin genes [35]. Recently, also
desmocollin-2 (DSC2), was identified as a direct target
of miR-29b in mouse keratinocytes [36], suggesting a po-
tential direct involvement of this miRNA in ACM.
miR-1183 on the other hand was identified as a putative
serum biomarker for rheumatic heart disease [37]. Ana-
lyses on the validated target genes of the ACM-specific
miRNAs revealed their involvement in ACM related
pathways, such as “extracellular matrix organization”.
These results, along with the literature mentioned above,
provide evidence for a potential prominent role of miR-
NAs in the ACM pathogenesis or phenotype mainten-
ance driven by CStCs.
Among the significantly differentially expressed genes
were also some potentially interesting candidates:
PCDH1, the strongest differentially expressed gene,
highly expressed in control and very low in ACM sam-
ples, encodes the protocadherin 1 membrane protein. El-
evated expression of PCDH1 was found to be related to
higher cell aggregation activity [38]. Among the stron-
gest up-regulated genes in ACM was also SEMA3D
which has been implicated in vascular development and
which can inhibit cell motility and tubulogenesis [39].
PCDH1 and SEMA3D were however not de-regulated in
all tested cases of the extended validation set, possibly
due to a different genetic background of the analyzed
ACM cases, and suggesting that different pathways
might contribute to ACM in its different subtypes. An-
other interesting differentially expressed gene was
NEDD9, a focal adhesion protein that acts as a scaffold
to regulate signaling complexes important in cell attach-
ment, migration and invasion [40]. Fibroblasts from
NEDD9 −/− mice showed significantly decreased adhe-
sion strength [41] while over-expression of NEDD9 was
shown to enhance cell speed and haptotaxis towards fi-
bronectin [42]. NEDD9 is also a validated target gene of
the ACM-specific miRNA miR-29-3p and of
miR-18a-5p, a miRNA also more than two-fold
up-regulated in ACM which regulation did however not
reach significance levels (adjusted p-value = 0.08). Its
more than two-fold down-regulation might hence be
mediated or consolidated by these miRNAs.
In analyzing the expression of genes with
ACM-associated variants we found that five of the 13
analyzed genes, namely CTNNA3, DES, DSC2, PLN and
RYR2, were not expressed. Therefore, potential patho-
genic effects of mutations in those genes is unlikely to
be mediated by CStCs.
By evaluating the expression of target genes from the
ACM-specific miRNAs we found them to be signifi-
cantly, albeit only slightly, lower expressed in ACM sam-
ples. This moderate downregulation was not completely
unexpected given the comparably low expression of the
miRNAs and the current opinion of miRNAs acting pre-
dominantly through fine-tuning gene expression [43,
44].
The functional network analysis resulted in some in-
teresting clusters of related genes. Among these was the
functional module FM_4 containing 9 differentially
expressed genes, four of which encode lipid transport
proteins. These proteins might play a role in the lipid ac-
cumulation described in ACM CStCs. Genes from two
other modules, FM_1 containing collagen encoding
genes and FM_6 inflammatory response related genes,
might be involved in the molecular events leading to fi-
brosis in ACM. Regarding the analysis of the combined
network, an interesting cluster was c0703, a cluster con-
sisting of 16 genes with 13 being involved in ephrin re-
ceptor signaling. The membrane bound Eph receptors
and ligands are involved in a wide array of developmen-
tal processes including cardiovascular, with one of their
most prominent biological functions being the modula-
tion of cell adhesion [45]. EphB receptors and ephrins
are part of the genetic program activated by β–catenin/
Wnt signaling [46]. Eph-ephrin signaling has also been
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implicated in cardiac stem cell migration into injured
tissue after myocardial infarction [47] and has even been
proposed as new therapeutic target for that disease [48].
Also an involvement in the modulation of electrical
coupling between cardiomyocytes has been reported
[49].
Limitations of the study
At last some limitations of the present study have to be
acknowledged. The results presented here base on cul-
tured cells and may hence not be directly expanded to
CStCs in their original microenvironment. Different mu-
tations in desmosomal genes might also have an impact
on the expression profiles of the cells. Also, it is cur-
rently unclear if ACM pathogenesis and disease progres-
sion is variant-specific or caused by a common canonical
pathway. The small numbers of available ACM cases
without any or with common mutations precluded how-
ever such mutation-specific differential expression ana-
lyses in the present data set. In addition, individuals in
the present study do not share a similar genotype and
thus any changes possibly identified between samples
can not be attributed exclusively to specific variants or
sets of variants in specific ACM-related genes. This in-
teresting aspect could however be analyzed in future
studies based on samples from individuals with similar
genetic background, such as affected and non-affected
individuals from the same family.
The small number of biological replicates used in the
genome wide screens represent another limitation of the
study and hence not all of the results might apply to
ACM in general. Nevertheless, we could validate the
main findings in a larger set of ACM patients and con-
trols. Still, due to the limited number of samples, the
present study should be considered as initial,
hypothesis-generating only and further studies evaluat-
ing the interconnection between the networks regarding
the progression of the disease are needed to fully
characterize ACM pathogenesis. Regarding the low
number of replicates, it is however also important to
highlight that ACM is a rare disease with low incidence
in the population [1, 2] and that it is difficult to obtain
CStCs from ACM patients due to the small rate of pa-
tients that undergo cardiac biopsies.
Selection of appropriate control samples is crucial for
any study. All control samples used for transcriptome
analysis and miRNA profiling derive from deceased indi-
viduals and might thus not be completely identical to bi-
opsies from living hearts. By taking the samples from
deceased organ donors without heart disease, which en-
sures special care to the explanted organs, we tried to
minimize any potential biases. CStCs from control sam-
ples were also generated using the same protocols and
cultured under the same conditions as CStCs from
ACM individuals.
Due to the phenotypic overlap of ACM with those of
other cardiomyopathies, particularly with the arrhythmic
form of idiopathic dilated cardiomyopathy (DCM) [50],
we can not completely exclude the miRNA and gene ex-
pression patterns presented here being shared across
some cardiomyopathies. Recently, genetic overlaps be-
tween ACM and DCM have been described: mutations
in genes encoding desmosomal proteins have been re-
ported in DCM cases [51] and mutations in TTN [50],
PLN [52] and FLNC [53] have been associate with both
ACM and DCM. Abnormalities such as epsilon waves
and right ventricular dilation, considered classical hall-
marks of ACM, have been described recently in patients
with Brugada syndrome [54, 55], along with mutations
in the PKP2 gene [56]. We can therefore not exclude
that the identified molecular signatures are specific for
ACM and do not overlap, at least to a certain degree,
with signatures in other primary cardiomyopathies. Still,
for the potential overlap with DCM, it has to be noted
that the shared phenotypic and structural overlap of
both diseases is seen in end-stage heart failures, while
the results in this study have been performed in
early-stage ACM patients.
Finally, all of the analyzed individuals in this study are
male, and some conclusions or results might thus not be
applicable to female ACM patients. Despite the lower
prevalence of ACM in females, it would however be of
utmost interest, also in the light of gender medicine, to
dissect in future studies gender-specific differences in
ACM disease development and progression.
Conclusions
We determined for the first time the coding and
non-coding transcriptome of ACM in cardiac stromal
cells. We found evidence for a potential prominent role
of miRNAs in ACM pathogenesis or phenotype main-
tenance. Due to the small sample sizes used for whole
genome expression profiling, the presented results might
however not be extended to all cell types involved in
ACM or to all different subtypes of ACM. Taken to-
gether, the comprehensive data set and the results pre-
sented here might serve as a resource for future studies
elucidating the role of the identified genes, miRNAs or
pathways in ACM.
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